Epicentre/Médecins Sans Frontières, in collaboration with other IMVACS partners, is conducting the CoSAV-R21 trial in southern Chad to identify the most effective delivery strategy for the R21/Matrix-M™ malaria vaccine for children under five in areas with high seasonal malaria transmission. 👉 Watch the video to learn more:https://youtu.be/l-yCwbBU4jI?si=lwQmxET1NO7_TNU9

The first survey was conducted in Mali (20th Nov – 6th Dec 2025), involving 824 children (412 in the control arm and 412 in the intervention arm) across 16 clusters. In Burkina Faso (18th Nov – 3rd Dec 2025), the first survey involved 824 children (412 in the control arm and 412 in the intervention…

On 20th November 2025, the IMVACS Consortium celebrates World Children’s Day 🌍 with the release of a short video, renewing its promise, dedication, and commitment to ensuring a brighter, healthier future for children in Mali and Burkina Faso.

Fieldworkers were trained on the qualitative and quantitative components of the IMVACS trial during a workshop held in November 2025 in Bamako (Mali) and Nanoro (Burkina Faso).

Some members of our IMVACS team proudly attended the ASTMH 2025 Annual Meeting (9-13th November, Toronto), one of the leading international conferences in global health.

📅 24th October 2025📍 Dioïla District, Mali👥 Participants enrolled in the IMVACS study to date: 28,837 It’s a wrap!For this year, the IMVACS team has successfully completed all four rounds of R-21 vaccine administration — in Mali from October 9th to 13th, and in Burkina Faso from October 16th to 19th.

📅 1st October 2025📍 Dioïla District, Mali👥 Participants enrolled in the IMVACS study to date: 28,096 Back to Mali for the third page of our field diary, where the story continues to unfold.

📅 8th August 2025📍 Boussé District, Burkina Faso👥 Participants enrolled in the IMVACS study to date: 23,774 The IMVACS journey continues: our second diary page straight from the field takes us to Burkina Faso.

SAFLI-R21-10 is an ancillary study conducted within the framework of the IMVACS project and designed to compare the safety, reactogenicity, and humoral immunogenicity of the 10-dose formulation of R-21/Matrix-M with 2-Phenoxyethanol preservative vs the safety, reactogenicity, and humoral immunogenicity of the 2-dose formulation of R21/Matrix-M vaccine.

📅 29th July 2025📍 Kola Cscom, Dioïla District, Mali👥 Participants enrolled in the IMVACS study to date: 23,227 The first diary page that brings to life the daily efforts of our field team and highlights the ongoing journey of the IMVACS trial.